on Bb Biotech (isin : CH0038389992)
BB Biotech AG Reports CHF 241 Million Net Loss for Q1 2025
BB Biotech AG, an investment company based in Switzerland, has released its interim report for the first quarter of 2025. The company reported a net loss of CHF 241 million for the period ending March 31, 2025. This contrasts with a profit of CHF 260 million during the same period in 2024.
The interim results reflect the fluctuations in the share prices of the companies within BB Biotech's investment portfolio. The full report is available on their website. BB Biotech specializes in investing in innovative drug developers, primarily in the US and Western Europe.
BB Biotech AG is listed on both the Swiss and German stock exchanges, with Bellevue Asset Management AG overseeing investment decisions through comprehensive research and strategy.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bb Biotech news